MABS-02

MABS-02 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Manhattan BioSolutions (also referred to as Manhattan Institute in some pipeline contexts) for the treatment of solid tumors and orphan diseases. The program is built upon a proprietary "Dual LP" platform, which features a dual linker-payload architecture. The payload is specifically designed to target RNA and DNA, providing a potent mechanism for inducing apoptosis in cancer cells. While the specific cell-surface antigen targeted by the antibody component has not been widely disclosed, the program represents a novel approach to ADC design by focusing on nucleic acid-directed cytotoxicity.